Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Gilles A. Salles, MD, PhD

Advertisement

Articles by Gilles A. Salles, MD, PhD

Dr. Salles on Improving Immune Respone in Follicular Lymphoma

ByGilles A. Salles, MD, PhD
February 14th 2017

Gilles A. Salles, MD, PhD, Centre Hospitalier Lyon-Sud, discusses improving immune response in follicular lymphoma.

Advertisement

Latest Updated Articles

  • Dr. Salles on Improving Immune Respone in Follicular Lymphoma
    Dr. Salles on Improving Immune Respone in Follicular Lymphoma

    February 14th 2017



Advertisement
Advertisement

Trending on OncLive

1

Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC

2

Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC

3

Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC

4

Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC

5

Dr Liu on Building on the ADRIATIC Regimen in Limited-Stage Small Cell Lung Cancer

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us